Literature DB >> 26970432

A win ratio approach to comparing continuous non-normal outcomes in clinical trials.

Duolao Wang1, Stuart Pocock2.   

Abstract

Clinical trials are often designed to compare continuous non-normal outcomes. The conventional statistical method for such a comparison is a non-parametric Mann-Whitney test, which provides a P-value for testing the hypothesis that the distributions of both treatment groups are identical, but does not provide a simple and straightforward estimate of treatment effect. For that, Hodges and Lehmann proposed estimating the shift parameter between two populations and its confidence interval (CI). However, such a shift parameter does not have a straightforward interpretation, and its CI contains zero in some cases when Mann-Whitney test produces a significant result. To overcome the aforementioned problems, we introduce the use of the win ratio for analysing such data. Patients in the new and control treatment are formed into all possible pairs. For each pair, the new treatment patient is labelled a 'winner' or a 'loser' if it is known who had the more favourable outcome. The win ratio is the total number of winners divided by the total numbers of losers. A 95% CI for the win ratio can be obtained using the bootstrap method. Statistical properties of the win ratio statistic are investigated using two real trial data sets and six simulation studies. Results show that the win ratio method has about the same power as the Mann-Whitney method. We recommend the use of the win ratio method for estimating the treatment effect (and CI) and the Mann-Whitney method for calculating the P-value for comparing continuous non-Normal outcomes when the amount of tied pairs is small.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Hodges and Lehmann method; Mann-Whitney test; non-normal outcome; treatment effect; win ratio

Mesh:

Year:  2016        PMID: 26970432     DOI: 10.1002/pst.1743

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  6 in total

1.  The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.

Authors:  Gaohong Dong; Lu Mao; Bo Huang; Margaret Gamalo-Siebers; Jiuzhou Wang; GuangLei Yu; David C Hoaglin
Journal:  J Biopharm Stat       Date:  2020-06-17       Impact factor: 1.051

2.  Weighted win loss approach for analyzing prioritized outcomes.

Authors:  Xiaodong Luo; Junshan Qiu; Steven Bai; Hong Tian
Journal:  Stat Med       Date:  2017-03-26       Impact factor: 2.373

3.  Group sequential methods for the Mann-Whitney parameter.

Authors:  Claus P Nowak; Tobias Mütze; Frank Konietschke
Journal:  Stat Methods Med Res       Date:  2022-06-13       Impact factor: 2.494

4.  On recurrent-event win ratio.

Authors:  Lu Mao; KyungMann Kim; Yi Li
Journal:  Stat Methods Med Res       Date:  2022-03-29       Impact factor: 2.494

5.  Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.

Authors:  Mark C Petrie; Subodh Verma; Kieran F Docherty; Silvio E Inzucchi; Inder Anand; Jan Belohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andre Dukát; Junbo Ge; Jonathan Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Pham Nguyen Vinh; Morten Schou; Sergey Tereshchenko; Lars Køber; Mikhail N Kosiborod; Anna Maria Langkilde; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon; Per Johanson; Peter J Greasley; David Boulton; Olof Bengtsson; Pardeep S Jhund; John J V McMurray
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

6.  Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization.

Authors:  Ross L Peterson; David M Vock; Abdel Babiker; John H Powers; Sally Hunsberger; Brian Angus; Armando Paez; James D Neaton
Journal:  Contemp Clin Trials Commun       Date:  2019-06-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.